Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.37 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211911 | 1.00 | IRAK4 (0.37) | IRAK4DUTGABRA1GABRG2GABRB3 | |
| SCHEMBL964133 | 1.00 | IRAK4 (0.37) | IRAK4DUTGABRA1GABRG2GABRB3 | |
| SCHEMBL3282024 | 0.91 | IRAK4 (0.36) | IRAK4DUT | |
| SCHEMBL21802067 | 0.91 | IRAK4 (0.36) | IRAK4DUT | |
| SCHEMBL3282030 | 0.91 | IRAK4 (0.36) | IRAK4DUT | |
| SCHEMBL23363973 | 0.84 | DUT (0.35) | IRAK4DUT | |
| SCHEMBL16447361 | 0.84 | DUT (0.35) | IRAK4DUT | |
| SCHEMBL23364207 | 0.84 | DUT (0.35) | IRAK4DUT | |
| SCHEMBL2453167 | 0.81 | IRAK4 (0.38) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5027911 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61207392-A | — | — | None | — | — | JP | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-08-05 | — | — | US | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20240391871-A1 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2024-11-28 | — | — | US | disclosed |
| EP-3240543-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4405333-A1 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES AND MEDICAL USES THEREOF | Atrogi AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| CN-118215652-A | Substituted hydroxymethyl pyrrolidines and medical uses thereof | 阿托基公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20040235864-A1 | Jun kinase inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| US-6734206-B1 | POTENT OCULAR HYPOTENSIVES THAT ARE PARTICULARLY SUITED FOR THE MANAGEMENT OF GLAUCOMA | ALLERGAN, INC. | 2004-05-11 | — | — | US | disclosed |
| EP-1373269-A1 | JUN KINASE INHIBITORS | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002081475-A1 | JUN KINASE INHIBITORS | EISAI CO., LIMITED (JP) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
| US-5736549-A | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE, USED FOR TREATING OR PREVENTING TISSUE REJECTION OR SELECTIVE SUPPRESSION OF MAMMALIAN T-CELL FUNCTION | CHIROSCIENCE LIMITED (GB) | 1998-04-07 | — | — | US | disclosed |
| EP-0784624-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | Chiroscience Limited (GB) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996011200-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| JP-S61207392-A | PYRROLIDONE DERIVATIVE AND PRODUCTION THEREOF | AJINOMOTO CO INC | 1986-09-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391871-A1 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES AND MEDICAL USES THEREOF | CYP3A5, PRMT5, CYP11B2 | IRAK4 3687/4885DUT 787/4885GABRA1 1671/4885 |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | IRAK4 3641/4885DUT 3160/4885GABRA1 1964/4885 |
| US-20040235864-A1 | Jun kinase inhibitors | NFKBIA, JUN, AIFM1 | IRAK4 362/4885DUT 4251/4885GABRA1 3400/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | IRAK4 3174/4885DUT 3747/4885GABRA1 2149/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | IRAK4 3399/4885DUT 2255/4885GABRA1 2027/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | IRAK4 3161/4885DUT 4095/4885GABRA1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.